Amgen kicks back I/O drug at center of $500M deal, leaving biotech partner alone to ponder next steps

Just ahead of a planned Phase I readout, Amgen is punting back an immuno-oncology drug to Molecular Partners.

Amgen cited a “strategic pipeline review” for the decision to return rights to MP0310, previously named AMG 506, to the biotech. Like the rest of Molecular Partners’ pipeline, it’s a DARPin —...

Click to view original post